TY1A-ER1 Antibody

What is TY1A-ER1 Antibody and what does it recognize?

TY1A-ER1 Antibody is designed to recognize Thymocyte differentiation antigen 1 (Thy-1/CD90), a glycosylphosphatidyl inositol (GPI)-linked cell surface glycoprotein. Thy-1 is expressed on numerous cell types and regulates signals affecting cell adhesion, migration, differentiation, and survival. The antibody specifically targets epitopes of the Thy-1 protein, which plays important roles in cellular signaling pathways. When designing experiments, researchers should note that antibody recognition can be affected by the conformational state of Thy-1, particularly whether it retains its GPI anchor .

What are the main applications for TY1A-ER1 Antibody in research?

TY1A-ER1 Antibody can be utilized in multiple experimental techniques including:

• Immunoblotting/Western blotting (with important caveats regarding soluble vs. membrane-bound forms)

• Immunoprecipitation procedures

• Flow cytometry for cell surface expression analysis

• Immunohistochemistry of tissue sections

• Immunofluorescence microscopy for localization studies

• ELISA detection of Thy-1 in biological fluids

The antibody is particularly valuable for studying Thy-1's involvement in cellular stress responses, as Thy-1 shedding has been observed in cytokine-stimulated lung fibroblasts and detected in various biological fluids including serum, cerebrospinal fluid, wound fluid, synovial fluid, and urine .

How does sample preparation affect TY1A-ER1 Antibody recognition?

Sample preparation significantly impacts TY1A-ER1 Antibody recognition due to Thy-1's GPI anchor. Research demonstrates that delipidation (removal of the GPI anchor) induces stable conformational changes in Thy-1 that alter antibody affinity. Many commercially available monoclonal antibodies cannot detect soluble (delipidated) Thy-1 by immunoblotting . When preparing samples:

• Membrane fractions should be carefully isolated to preserve GPI-anchored Thy-1

• Detergent selection is critical for maintaining protein conformation

• Denaturing conditions may affect epitope accessibility

• Consider phospholipase treatments when comparing membrane-bound versus soluble forms

How can researchers differentiate between membrane-bound and soluble Thy-1 in experimental samples?

Differentiating between membrane-bound and soluble Thy-1 requires multiple methodological approaches:

• Ultracentrifugation: Separate membrane fragments/vesicles (100,000 × g for 60-90 minutes) to isolate insoluble fractions

• Detergent phase separation: Use Triton X-114 to separate GPI-anchored proteins into detergent phase

• Antibody panel approach: Employ both N-terminal and C-terminal targeted antibodies

• Size-based analysis: Compare molecular weights before and after deglycosylation

• PI-PLC treatment: Enzymatic release of GPI-anchored proteins as control

Research indicates that what was previously thought to be soluble Thy-1 in normal human lung fibroblast conditioned media is actually insoluble, suggesting retention of the GPI anchor in membrane fragments or vesicles . This finding necessitates careful experimental design when studying Thy-1 release.

What controls should be included when using TY1A-ER1 Antibody in immunodetection experiments?

Rigorous control implementation is essential for accurate data interpretation:

Since antibody recognition is affected by Thy-1's conformational state with or without its GPI anchor, researchers should include controls representing both states .

How can inconsistent TY1A-ER1 Antibody detection across different experimental platforms be resolved?

When facing inconsistent detection:

• First confirm antibody specificity through Western blotting against positive controls

• For flow cytometry applications, optimize fixation protocols that preserve GPI-anchored protein conformation

• For immunohistochemistry, compare different antigen retrieval methods systematically

• When detecting Thy-1 in biological fluids, employ ultracentrifugation to isolate potential membrane-associated forms

• Test multiple antibody clones targeting different Thy-1 epitopes

• Consider native vs. denaturing conditions for each application

Recent findings suggest that most Thy-1 in biological fluids retains its GPI anchor and may be associated with membrane fragments or vesicles, which affects detection methods differently .

How should experiments be designed to study Thy-1 shedding in response to cellular stress?

When investigating Thy-1 shedding:

• Cell treatment protocol:

  • Culture fibroblasts to 70-80% confluence

  • Treat with pro-inflammatory cytokines (TNF-α, IL-1β, or IFN-γ) at physiologically relevant concentrations

  • Include time-course analysis (2, 6, 12, 24, 48h) to capture kinetics

• Detection strategy:

  • Parallel analysis of cell surface Thy-1 by flow cytometry

  • Conditioned media collection with protease inhibitors

  • Ultracentrifugation to separate truly soluble from vesicle-associated Thy-1

  • Immunoblotting of both fractions

• Validation approaches:

  • RT-PCR to monitor Thy-1 transcription during treatment

  • Inhibitor studies (GPI-specific phospholipases, proteases)

  • Microscopy for membrane integrity assessment

Research indicates that cytokine stimulation of lung fibroblasts leads to apparent Thy-1 shedding, but careful analysis reveals this may represent release of membrane-associated rather than truly soluble Thy-1 .

What experimental approaches can resolve contradictory findings regarding Thy-1 detection in biological fluids?

Resolving contradictory findings requires systematic investigation:

• Sample fractionation:

  • Low-speed centrifugation to remove cells

  • Medium-speed centrifugation to remove large debris

  • High-speed ultracentrifugation to isolate microvesicles

  • Ultrafiltration to concentrate truly soluble proteins

• Deglycosylation analysis:

  • Compare molecular weights before and after deglycosylation

  • Use multiple deglycosylation enzymes (PNGase F, O-glycosidase)

• Detailed characterization:

  • Mass spectrometry to confirm protein identity

  • Epitope mapping to identify conformational changes

  • GPI anchor detection using specific lipid analysis

• Method validation:

  • Spike-in experiments with known quantities of recombinant Thy-1

  • Parallel analysis using multiple antibody clones

Studies have shown that Thy-1 detected in various biological fluids (serum, CSF, wound fluid, synovial fluid) may maintain its GPI anchor within membrane fragments or vesicles, explaining detection inconsistencies .

Why might TY1A-ER1 Antibody fail to detect Thy-1 in Western blots despite confirmation by other methods?

Western blot detection failures may occur due to:

• Conformational dependence: Delipidation of Thy-1 causes stable conformational changes affecting antibody recognition. TY1A-ER1 may recognize native but not denatured Thy-1 .

• Technical optimization strategies:

  • Test different sample preparation methods (native vs. denaturing conditions)

  • Reduce SDS concentration in sample buffer

  • Try different transfer methods (wet vs. semi-dry)

  • Optimize blocking reagents to reduce background

  • Test multiple antibody concentrations

• Alternative approaches:

  • Use epitope-tagged recombinant Thy-1 as detection control

  • Compare results with multiple anti-Thy-1 antibodies targeting different epitopes

  • Consider native PAGE for conformationally sensitive epitopes

Studies confirm that widely available monoclonal antibodies to human Thy-1 cannot detect soluble Thy-1 by immunoblotting due to conformational changes after GPI anchor removal .

How can researchers optimize TY1A-ER1 Antibody conditions for detecting membrane-associated Thy-1 in vesicles?

Optimizing detection of vesicle-associated Thy-1:

• Isolation protocol:

  • Sequential centrifugation (300×g → 2,000×g → 10,000×g → 100,000×g)

  • Density gradient separation for vesicle purification

  • Size exclusion chromatography for vesicle fractionation

• Vesicle characterization:

  • Nanoparticle tracking analysis for size distribution

  • Electron microscopy for morphological assessment

  • Western blotting for vesicle markers (CD63, CD81)

• Antibody optimization:

  • Titrate antibody concentrations

  • Test fixation and permeabilization methods

  • Compare direct labeling vs. secondary detection systems

Research indicates that what appears as soluble Thy-1 in biological fluids may actually be vesicle-associated, requiring careful isolation and analysis procedures .

How might post-translational modifications of Thy-1 affect TY1A-ER1 Antibody recognition and biological function?

Post-translational modifications of Thy-1 represent an important research frontier:

• Glycosylation analysis:

  • Thy-1 contains multiple N-glycosylation sites affecting conformation

  • Different cell types produce Thy-1 with varied glycosylation patterns

  • Glycosylation changes during cellular stress may alter antibody recognition

• GPI anchor variations:

  • Lipid composition of GPI anchors varies by cell type and condition

  • Different GPI structures may affect membrane microdomain localization

  • GPI modification enzymes may be regulated during cell activation

• Methodological approaches:

  • Glycan profiling using mass spectrometry

  • Site-directed mutagenesis of glycosylation sites

  • Inhibitors of specific glycosylation pathways

  • Lipidomic analysis of GPI anchor composition

These modifications likely affect not only antibody affinity but also ligand binding and biological function of soluble versus membrane-associated Thy-1 forms .

What are emerging methods for studying the functional differences between GPI-anchored and soluble Thy-1?

Cutting-edge approaches include:

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize Thy-1 in membrane microdomains

  • FRET analysis for protein-protein interactions

  • Live-cell imaging with fluorescently tagged Thy-1 variants

• Functional assays:

  • Cell adhesion and migration in response to different Thy-1 forms

  • Signaling pathway activation (phospho-proteomics)

  • Comparison of recombinant Thy-1 with/without GPI anchor

• Genetic approaches:

  • CRISPR/Cas9 modification of endogenous Thy-1

  • Creation of GPI-anchor mutants

  • Reporter systems for Thy-1 shedding

• Biophysical characterization:

  • Surface plasmon resonance for binding kinetics

  • Circular dichroism to detect conformational changes

  • Hydrogen-deuterium exchange mass spectrometry

These methods can help elucidate how conformational changes in Thy-1 after delipidation affect not only antibody recognition but also biological function in different contexts .